Jolanta M. Siller-Matula

Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

Interspecies differences in coagulation profile.

Reproducibility and standardized reporting of the vasodilator-stimulated phosphoprotein phosphorylation assay.

Calcium-channel blockers reduce the antiplatelet effect of clopidogrel.

Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel.

The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation.

Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers.

Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.

The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo.

An experimental model to study isolated effects of thrombin in vivo.

Targeting von Willebrand factor and platelet glycoprotein Ib receptor.

Ticagrelor: from discovery to Phase III clinical trial.

Addition of omeprazole to dual antiplatelet therapy with clopidogrel plus aspirin lowers the risk of upper gastrointestinal bleeding.

Thrombin as a multi-functional enzyme. Focus on in vitro and in vivo effects.

The effect of erythropoietin on platelet and endothelial activation markers: a prospective trial in healthy volunteers.

ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion.

Continuous thrombin infusion leads to a bleeding phenotype in sheep.

Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin.

Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomized controlled trial.

Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study.

Why have studies of tailored anti-platelet therapy failed so far?

Response variability to P2Y12 receptor inhibitors: expectations and reality.

Association between the rs342293 polymorphism and adverse cardiac events in patients undergoing percutaneous coronary intervention.

[Dual platelet inhibitors in intensive care units].

Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention.

The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention.

How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors--is an algorithm the answer?

Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.

Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE).

Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention.

Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis.

Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor.

Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls.

Distribution of clinical events across platelet aggregation values in all-comers treated with prasugrel and ticagrelor.

Abciximab as a bridging strategy to overcome morphine-prasugrel interaction in STEMI patients.

Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study.

Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.

Platelets redox balance assessment: Current evidence and methodological considerations.

Interdependence between osteoprotegerin and active von Willebrand factor in long-term cardiovascular mortality prediction in patients undergoing percutaneous coronary intervention.

Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (vention o Thromboembolic Events-uropean egistry in trial ibrillation).

Clopidogrel in Critically Ill Patients.

Ticagrelor - toward more efficient platelet inhibition and beyond.

Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC).

Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy.

Assessment of adherence to medication in patients after myocardial infarction treated with percutaneous coronary intervention. Is there a place for newself-reported questionnaires?

Coming Closer to Personalized Medicine in Transcatheter Aortic Valve Replacement.

Cangrelor Induces More Potent Platelet Inhibition without Increasing Bleeding in Resuscitated Patients.

Switching between P2Y antagonists - From bench to bedside.

Thrombotic and hemorrhagic burden in women: Gender-related issues in the response to antithrombotic therapies.

Platelet reactivity patterns in patients treated with dual antiplatelet therapy.

Optimal Timing of P2Y12 Inhibitor Loading in Patients Undergoing PCI: A Meta-Analysis.

Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).

[Aortic valve disease].

Effectiveness of Antiplatelet Drugs Under Therapeutic Hypothermia: A Comprehensive Review.

Incidence, predictors, and prognosis of premature discontinuation or switch of prasugrel or ticagrelor: the ATLANTIS - SWITCH study.

Shedding Light on Long-Term Effects of Early Antiplatelet Strategies After Fibrinolytic Treatment in STEMI.

Differential Effects of Ticagrelor With or Without Aspirin on Platelet Reactivity and Coagulation Activation: A Randomized Trial in Healthy Volunteers.

Significance of circulating microRNAs in diabetes mellitus type 2 and platelet reactivity: bioinformatic analysis and review.

Transcatheter Aortic Valve Replacement Is Associated with Less Oxidative Stress and Faster Recovery of Antioxidant Capacity than Surgical Aortic Valve Replacement.

Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients.

Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups.

Bioresorbable Vascular Scaffolds-Dead End or Still a Rough Diamond?

Ticagrelor attenuates the increase of extracellular vesicle concentrations in plasma after acute myocardial infarction compared to clopidogrel.

Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing.

Transcatheter versus surgical aortic valve replacement in low-risk patients: a meta-analysis of randomized trials.

Sex and gender in cardiovascular medicine: presentation and outcomes of acute coronary syndrome.

Impact of Preadmission Morphine on Reinfarction in Patients With ST-Elevation Myocardial Infarction Treated With Percutaneous Coronary Intervention: A Meta-Analysis.

Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a Joint Position Paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI).

Antithrombotic agents for primary and secondary prevention of cardiovascular events in patients with end-stage renal disease on chronic hemodialysis.

Non-Vitamin K Oral Anticoagulants (NOAC) Versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type.

Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium.

Inflammatory state does not affect the antiplatelet efficacy of potent P2Y12 inhibitors in ACS.

Prediction for Contrast Volume in Transcatheter Aortic Valve Replacement - Important but Modifiable?

Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients.

Adaptive development of concomitant secondary mitral and tricuspid regurgitation after transcatheter aortic valve replacement.

Updated overview of evidence on optimal antithrombotic therapy in patients with atrial fibrillation undergoing percutanous coronary intervention.

von Willebrand Factor Predicts Mortality in ACS Patients Treated with Potent P2Y12 Antagonists and is Inhibited by Aptamer BT200 Ex Vivo.

Medication adherence and its determinants in patients after myocardial infarction.

Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry.

Interleukin-6 level is a powerful predictor of long-term cardiovascular mortality in patients with acute coronary syndrome.

MicroRNAs and Long Noncoding RNAs in Coronary Artery Disease: New and Potential Therapeutic Targets.

MicroRNAs as Biomarkers of Systemic Changes in Response to Endurance Exercise-A Comprehensive Review.

Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines.

Cardiac arrest and related mortality in emergency departments in the United States: Analysis of the nationwide emergency department sample.

ACE2 Interaction Networks in COVID-19: A Physiological Framework for Prediction of Outcome in Patients with Cardiovascular Risk Factors.

Editorial: Antithrombotic Treatment in Transcatheter Structural Cardiac Interventions and After Cardiac Device Implantation.

Right ventricular function and outcome in patients undergoing transcatheter aortic valve replacement.

Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and the Risk of SARS-CoV-2 Infection or Hospitalization With COVID-19 Disease: A Systematic Review and Meta-Analysis.

Sex Differences in Treatment and Outcomes in Non-ST-Elevation Acute Coronary Syndrome: A Persistent Disparity.